Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

From Pfizer to AstraZeneca and the Omnicom-IPG Merger, the industry has seen a number of executive moves during this year.

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...

Last year around this time, several leading drugmakers announced significant M&A deals to help fill their pipelines, including Bristol-Myers Squibb's (BMY) proposed takeovers of Karuna and RayzeBio, ...

“But teaming with Erik De Clercq, a doctor from Leuven, Belgium who is still alive, and later with John Martin, who ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

This growth, in large part driven by tech and the continuing AI revolution, has surprised value investors and professional ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...